Spyre Therapeutics, Inc.
SEC CIK 1636282 · SYRE · last insider filing 2026-06-26
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Harwin Peter Evan | Director | filed 2023–2026 |
| Fairmount Healthcare Fund II L.P. | Director | filed 2023–2026 |
| Henderson Michael Thomas | Director | filed 2023–2026 |
| Fairmount Funds Management LLC | Director | filed 2023–2026 |
| Kiselak Tomas | Director | filed 2023–2026 |
| Turtle Cameron | Director · Chief Executive Officer | filed 2023–2026 |
| Albers Jeffrey W. | Director | filed 2023–2026 |
| Stelzer Laurie | Director | filed 2023–2026 |
| Mckenna Mark C. | Director | filed 2024–2026 |
| Milligan Sandra | Director | filed 2024–2026 |
| Fairmount Healthcare Fund L.P. | Director | filed 2023–2023 |
| Fairmount Healthcare Co-Invest L.P. | Director | filed 2023–2023 |
| Magovcevic-Liebisch Ivana | Director | filed 2018–2023 |
| Cox Russell J. | Director | filed 2016–2023 |
| Lawton Alison Frances | Director | filed 2020–2023 |
| Smith Hunter C | Director | filed 2021–2023 |
| Goldberg Jeff Marc | Director · President and CEO | filed 2022–2022 |
| Souza Marcio | Director | filed 2021–2022 |
| Lawlis V Bryan | Director | filed 2018–2022 |
| Mahatme Sandesh | Director | filed 2016–2022 |
| Shanafelt Armen | Director | filed 2016–2022 |
| Quinn Anthony G. | Director · interim Chief Medical Officer | filed 2016–2022 |
| Baker Julian | Director | filed 2021–2021 |
| Baker Felix | Director | filed 2021–2021 |
| Baker Bros. Advisors LP | Director | filed 2021–2021 |
| Baker Brothers Life Sciences LP | Director | filed 2021–2021 |
| 667, L.P. | Director | filed 2021–2021 |
| Baker Bros. Advisors (GP) LLC | Director | filed 2021–2021 |
| Brownstein Sara | Director | filed 2021–2021 |
| Bruhn Suzanne Louise | Director | filed 2017–2020 |
| Georgiou George | Director | filed 2016–2018 |
| Lowe David George | Director · CEO and President | filed 2016–2017 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Burrows Scott L | Chief Financial Officer | filed 2023–2026 |
| Sloan Sheldon | Chief Medical Officer | filed 2024–2026 |
| King-Jones Heidy | See Remarks | filed 2023–2026 |
| Alspaugh Jonathan | President and CFO | filed 2021–2023 |
| Hanley Jr. Michael Conick | Chief Commercial Officer | filed 2019–2023 |
| Kastenmayer James Paul | Interim CEO & General Counsel | filed 2022–2023 |
| Neuman Linda L | Chief Medical Officer | filed 2023–2023 |
| Sloan Leslie | Chief Operating Officer | filed 2019–2022 |
| Weber Steven | VP, Controller&Princ Acctg Off | filed 2021–2022 |
| York Charles N II | Chief Financial Officer and VP | filed 2016–2020 |
| Rao Madduri Ravin | Chief Medical Officer | filed 2019–2020 |
| Schuchart Aaron | Chief Business Officer | filed 2017–2019 |
| Wooldridge James | Chief Medical Officer | filed 2017–2019 |
| Tyler Joseph E | VP, Manufacturing | filed 2016–2017 |
| Rowlinson Scott W | VP, Research | filed 2016–2017 |
| Hebel Henry | VP, Product Development | filed 2016–2017 |
| Rojas-Caro Sandra | Chief Medical Officer | filed 2016–2016 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.